Fig. 2From: Efficacy and safety of fremanezumab in patients with migraine and inadequate response to prior preventive treatment: subgroup analyses by country of a randomized, placebo-controlled trialPatients achieving ≥ 50% reduction in MMD during a) 12 weeks and at b) 4 weeks. MMD monthly migraine days. aP < 0.01 versus placebo. bP > 0.05 versus placebo. cP < 0.05 versus placebo. dP ≤ 0.001 versus placeboBack to article page